P-GP-A in English translation

• p-gp

Examples of using P-gp-a in Croatian and their translations into English

Iako prukaloprid može biti slabi supstrat P-glikoproteina(P-gp), u klinički važnim koncentracijama nije inhibitor P-gp-a.
Although prucalopride may be a weak substrate for P-glycoprotein(P-gp), it is not an inhibitor of P-gp at clinically relevant concentrations.

25 mg jedanput na dan), supstrata P-gp-a, nije utjecala na AUC ni Cmax digoksina.
digoxin(0.25 mg once a day), a P-gp substrate, did not affect digoxin AUC or Cmax.

Istovremena primjena deksametazona s tvarima koje se metaboliziraju putem CYP3A4 ili transportiraju putem P-gp-a može rezultirati povećanjem klirensa
Concomitant administration of dexamethasone with substances that are metabolised via CYP3A4 or transported by P-gp could lead to increased clearance

u crijevima ljudi i ne uzrokuje klinički značajno povišenje koncentracije digoksina(supstrata P-gp-a), ali povećava AUC u plazmi za 11.
does not result in clinically relevant increases in concentrations of digoxin(a P-gp substrate), with an 11% increase in plasma AUC.

će na farmakokinetički profil karfilzomiba utjecati inhibitori ili induktori P-gp-a ili BCRP-a.
the pharmacokinetic profile of carfilzomib is unlikely to be affected by P-gp or BCRP inhibitors or inducers.

je bio primijenjen istodobno, zbog inhibicije P-gp-a vandetanibom.
when given together due to P-gp inhibition by vandetanib.

Podaci iz in vitro ispitivanja pokazuju da je ulipristalacetat mogući inhibitor P-gp-a pri klinički relevantnim koncentracijama u stijenci probavnog sustava prilikom apsorpcije.
In vitro data indicate that ulipristal acetate may be an inhibitor of P-gp at clinically relevant concentrations in the gastrointestinal wall during absorption.

In vitro eksperimenti s humanim Caco-2 stanicama ukazuju na to da je simeprevir supstrat P-gp-a.
In vitro experiments with human Caco-2 cells indicated that simeprevir is a substrate of P-gp.

slabi inhibitor P-gp-a u visokim koncentracijama.
a weak inhibitor of P-gp at high concentrations.

In vitro ispitivanja su pokazala da ibrutinib nije supstrat P-gp-a, niti drugih glavnih prijenosnika, osim OCT2.
In vitro studies indicated that ibrutinib is not a substrate of P-gp, nor other major transporters, except OCT2.

je supstrat za prijenosnik P-gp-a.
is a substrate for the P-gp transporter.

može povećati izloženost lijekovima koji su supstrati P-gp-a vidjeti dio 4.5.
may increase the exposure of medicinal products that are substrates for P-gp see section 4.5.

jaki inhibitor enzima CYP3A4 i P-gp-a, povisio je sistemsku izloženost prukalopridu za približno 40.
a potent inhibitor of CYP3A4 and of P-gp, increased the systemic exposure to prucalopride by approximately 40.

Ranolazin je umjeren do snažan inhibitor P-gp-a i blag inhibitor CYP3A4 pa može povećati koncentracije P-gp-a ili CYP3A4 supstrata u plazmi.
Ranolazine is a moderate to potent inhibitor of P-gp and a mild inhibitor of CYP3A4, and may increase plasma concentrations of P-gp or CYP3A4 substrates.

Mora se razmotriti odabir drugog istodobnog lijeka, koji nema, ili ima minimalan potencijal indukcije P-gp-a.
Selection of an alternate concomitant medicinal product with no or minimal P- gp induction potential should be considered.

Potreban je oprez kad se vemurafenib primjenjuje istodobno sa supstratima P-gp-a(npr. aliskirenom,
Caution should be exercised when dosing vemurafenib concurrently with P-gp substrates(e.g. aliskiren,

Istovremena primjena jednokratnih doza inhibitora P-gp-a ciklosporina A i fidaksomicina u zdravih dobrovoljaca rezultirala je četverostrukim povećanjem Cmax i dvostrukim povećanjem AUC-a fidaksomicina te povećanjem Cmax glavnog djelatnog metabolitaOP- 1118 za 9, 5 puta i AUC-a za 4 puta.
Co-administration of single doses of the P-gp inhibitor cyclosporine A and fidaxomicin in healthy volunteers, resulted in a 4- and 2-fold increase in fidaxomicin Cmax and AUC, respectively and in a 9.5 and 4-fold increase in Cmax and AUC, respectively, of the main active metabolite OP-1118.

U slučaju da bolesnica koja već prima olaparib treba liječenje inhibitorom P-gp-a, preporučuje se pažljiv nadzor zbog moguće pojave nuspojava povezanih s primjenom olapariba,
In the event that a patient already receiving olaparib requires treatment with a P-gp inhibitor, careful monitoring of olaparib associated adverse events and management of those

jakog inhibitora OATP(OATP1B1 i OATP1B3) i P-gp-a, dva puta dnevno, izloženost seleksipagu povećala se približno dvostruko,
a strong OATP(OATP1B1 and OATP1B3) and P-gp inhibitor, exposure to selexipag increased approximately 2-fold,

Očekuje se da će lijekovi koji induciraju aktivnost P-gp-a(npr. rifampicin,
Medicinal products that induce P-gp activity(e.g. rifampicin,